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Abstract: Atrial and brain natriuretic peptides (ANP and BNP, respectively) are cardiac hormones, secretions of which 
are markedly upregulated during cardiac failure, making their plasma levels clinically useful diagnostic markers. ANP and 
BNP exert potent diuretic, natriuretic and vasorelaxant effects, which are mediated via their common receptor, guanylyl 
cyclase (GC)-A (also called natriuretic peptide receptor (NPR)-A). Mice deficient for GC-A are mildly hypertensive and 
show marked cardiac hypertrophy and fibrosis that is disproportionately severe, given their modestly higher blood 
pressure. Indeed, the cardiac hypertrophy seen in these mice is enhanced in a blood pressure-independent manner and is 
suppressed by cardiomyocyte-specific overexpression of GC-A. These results suggest that the actions of a local cardiac 
ANP/BNP-GC-A system are essential for maintenance of normal cardiac architecture. In addition, GC-A was shown to 
exert its cardioprotective effects by inhibiting angiotensin II-induced hypertrophic signaling, and recent evidence suggests 
that regulator of G protein signaling (RGS) subtype 4 is involved in the GC-A-mediated inhibition of Gq-coupled 
hypertrophic signal transduction. Furthermore, several different groups have reported that functional mutations in the 
promoter region of the human GC-A gene are associated with essential hypertension and ventricular hypertrophy. These 
findings suggest that endogenous GC-A protects the heart from pathological hypertrophic stimuli, and that humans who 
express only low levels of GC-A are genetically predisposed to cardiac remodeling and hypertension. 
INTRODUCTION 
  Normal cardiac structure is maintained by a sophisticated 
set of mechanical and cellular “checks and balances”, 
disturbance of which leads to a process called remodeling 
[1]. Although this process is initially adaptive, the beneficial 
effects are transient, and chronic cardiac remodeling leads to 
pathological molecular, cellular and interstitial changes that 
hinder cardiac function and ultimately lead to heart failure 
[2, 3]. Among the genes upregulated in cardiac remodeling, 
there are two that encode peptide hormones, atrial natriuretic 
peptide (ANP) [4, 5] and brain natriuretic peptide (BNP) [6]. 
ANP and BNP are synthesized, processed and secreted 
exclusively by the heart [7,8]. In response to the over-
activation of various neurohumoral and mechanical stimuli 
that occur during heart failure, both the expression and 
secretion of ANP and BNP are dramatically upregulated, 
making their plasma levels clinically useful markers for the 
diagnosis and assessment of cardiac failure [9, 10]. Both 
natriuretic peptides exert potent diuretic, natriuretic and 
vasorelaxant effects through activation of their common 
receptor, guanylyl cyclase (GC)-A [also called natriuretic 
peptide receptor (NPR)-A] (Fig. (1)). GC-A is a prototype of 
plasma membrane-bound GCs, which serve as receptors that  
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produce cyclic GMP (cGMP) in response to ligand binding 
[11]. C-type natriuretic peptide (CNP), the third member of 
the natriuretic peptide family, exerts its biological actions 
through another GC-coupled receptor called GC-B. In 
addition, the third receptor called clearance receptor 
mediates the metabolism of the natriuretic peptides. Because 
GC-A signaling stimulated by ANP and BNP results in a 
decrease in cardiac pre- and after-load, their mobilization 
during cardiac failure is thought to be one of the 
compensatory mechanisms activated in response to heart 
damage. In addition to the hemodynamic effects of their 
actions as circulating hormones, recent evidences suggest 
that ANP and BNP also act as autocrine/paracrine hormones. 
In the present review, we discuss the cardioprotective 
functions of endogenous ANP and BNP, focusing in 
particular on their local effects within the heart. 
In Vitro Studies Using Cultured Cardiomyocytes 
  The role of ANP as an autocrine factor involved in 
regulating cardiac myocyte growth is suggested by early in 
vitro studies carried out using cultured cardiomyocytes.  
  Studies from Calderone et al. demonstrated the effects of 
exogenously applied ANP on heart cells [12]. Using cells 
cultured from neonatal rat heart, they observed that 
exogenously applied ANP caused concentration-dependent 
reductions in norepinephrine-stimulated incorporation of 
[
3H]-leucine in myocytes and [
3H]-thymidine in fibroblasts 
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levels, and 8-bromo-cGMP, a cGMP analogue, mimicked the 
growth-suppressing effects of ANP. In addition, ANP and 8-
bromo-cGMP similarly attenuated the 1-adrenergic recep-
tor-mediated increases in the mRNA level of proANP and 
decreases in the mRNA level of calcium ATPase in the 
sarcoplasmic reticulum (SR). The authors concluded that 
ANP diminishes the effects of norepinephrine on the growth 
of cardiac myocytes and fibroblasts, most likely via cGMP-
mediated inhibition of the Ca
2+ influx stimulated by 
norepinephrine. 
  In the opposite direction, we investigated the role of 
endogenously secreted ANP as an autocrine factor, treating 
cultured neonatal rat ventricular myocytes with HS-142–1, a 
non-selective receptor antagonist for GC-A and GC-B [13]. 
We found that the receptor antagonist increased both basal 
and phenylephrine-stimulated protein synthesis in a 
concentration-dependent manner, and these effects were 
accompanied by a significant increase in myocyte size. In 
addition, the expression of skeletal actin, -myosin heavy 
chain and ANP, markers of hypertrophy, were elevated by 
treatment with the antagonist under both basal and 
phenylephrine-stimulated conditions. Conversely, both a 
cGMP-specific phosphodiesterase inhibitor, zaprinast, and a 
cGMP analogue suppressed basal and phenylephrine-
stimulated protein synthesis. Thus, endogenous secretion of 
natriuretic peptides (ANP or BNP) from cardiomyocytes 
appears to inhibit cardiac myocyte hypertrophy under both 
basal and catecholamine-stimulated conditions, most likely 
via a cGMP-dependent process.  
 These  in vitro studies clearly suggest a local function of 
the natriuretic peptide system in the heart. However, since 
these studies were carried out using cultured neonatal cells, 
clarification of the physiological and pathophysiological 
effects of natriuretic peptides in vivo hearts was awaited for 
further investigation. In addition, although the results of 
cGMP and HS-142-1 implicated a role of GC-coupled 
receptors, it remained to be determined which receptor 
mediates the cardioprotective action of natriuretic peptides. 
 
Fig. (2). Cardiac Hypertrophy in GC-A KO. GC-A-deficient mice 
(GC-A KO) develop cardiac hypertrophy, as shown on the right.  
In Vivo Studies Using the Mice Deficient for GC-A 
  To verify the hypothesis generated by the in vitro studies, 
the cardiovascular effects of endogenous natriuretic peptide 
signaling in vivo have been examined using the genetically 
engineered mice. 
  Because ANP and BNP share a common receptor (i.e., 
GC-A), the absence of one peptide can presumably be 
 
Fig. (1). The mammalian natriuretic peptide system. The mammalian natriuretic peptide system is composed of at least three ligands (ANP, 
BNP and CNP) and three receptors (GC-A, GC-B and clearance receptor). ANP and BNP are cardiac hormones that are synthesized, 
processed and secreted by the heart. They exert their biological effects, which include diuresis, natriuresis and vasodilation, via a shared 
receptor, GC-A. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CNP, C-type natriuretic peptide; GC-A, guanylyl cyclase-A; 
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compensated for by the other. Therefore, to reveal the full 
effects of cardiac natriuretic peptide signaling, we generated 
mice that lacked endogenous GC-A (GC-A KO), and 
analyzed the cardiovascular phenotype [14-16]. As shown in 
Figs. (2 and 3), targeted deletion of the GC-A gene resulted 
in marked cardiac hypertrophy and fibrosis. Although GC-A 
KO mice also display mild hypertension, the cardiac 
hypertrophy was disproportionately severe, given the modest 
rise in blood pressure of the animal. In fact, other animal 
models that show similar increases in blood pressure do not 
exhibit the same degree of hypertrophy as GC-A KO mice 
[17, 18].  
  Independently, the research group led by Professors 
Smithies and Maeda at the University of North Carolina 
showed that mice lacking a functional Npr1 gene, which 
encodes NPR-A (i.e. GC-A), have elevated blood pressure 
and marked cardiac hypertrophy with interstitial fibrosis, 
resembling that seen in human hypertensive heart disease 
[19]. In their subsequent study, Knowles et al. reported that 
chronic treatment of GC-A KO with an ACE inhibitor, a 
diuretic, hydralazine or an angiotensin-receptor blocker, 
which all reduce blood pressure to the similar level as in 
wild-type mice, had no significant effect on the heart to body 
weight ratio [20]. Furthermore, in the reverse direction, 
pressure overload induced by transverse aortic constriction 
led to greater increases in ANP expression and in left 
ventricular weight to body weight ratio, in GC-A-KO mice 
than in wild-type mice [20]. Taken together, the authors 
concluded that the natriuretic peptide/GC-A system has 
direct antihypertrophic actions in the heart, independent of 
its role in blood pressure control. It is reported that targeted 
deletion of the proANP gene or proBNP gene also resulted in 
blood pressure-independent biventricular hypertrophy [21] or 
fibrosis [22], respectively, suggesting that a mechanism 
other than an increase in cardiac afterload exists for cardiac 
remodeling to be established in the mice lacking endogenous 
natriuretic peptides. In addition, since GC-A is expressed in 
the heart itself [23], it is suggested that this natriuretic 
peptide system acts in an autocrine/paracrine fashion to exert 
its cardioprotective effects.  
Cardiomyocyte-Specific Overexpression or Deletion of 
GC-A Gene 
  Additional insights have also been gained from 
conditional overexpression or disruption of the GC-A gene.  
  We generated transgenic mice in which the GC-A 
transgene was selectively overexpressed in cardiomyocytes 
[24]. Expression of this gene in the hearts of GC-A KO and 
wild-type mice did not alter blood pressure or heart rate in 
either group; however it did reduce the size of both normal 
myocytes in wild-type mice and hypertrophied myocytes in 
GC-A KO animals. Coincident with this reduction in 
myocyte size, cardiac levels of both mRNA and protein 
levels of ANP were significantly reduced. The genetic model 
thus separates the systemic regulation of cardiomyocyte size 
by blood pressure from the local regulation by myocardial 
effectors.  
  The moderation of cardiac hypertrophy by local GC-A 
signaling was also demonstrated in a set of sophisticated 
experiments performed in the laboratory of Professor Kuhn 
at the University of Munich in Germany [25]. To test 
whether local ANP levels modulate cardiomyocyte growth, 
this group used homologous loxP/Cre-mediated recom-
bination to selectively delete the GC-A gene in cardiomyo-
cytes, thereby circumventing the systemic, hypertensive 
 
Fig. (3). Cardiac Fibrosis in GC-A KO. GC-A-deficient (GC-A KO) mice develop cardiac fibrosis, as shown in right. Heart tissues were 
visualized after Masson-Trichrome staining. The fibrotic tissue is seen in blue.  48    Current Cardiology Reviews, 2009, Vol. 5, No. 1  Kishimoto et al. 
phenotype associated with germ line inactivation of GC-A. 
Mice with the cardiomyocyte-specific GC-A deletion 
exhibited mild cardiac hypertrophy and a marked increase in 
the transcription of cardiac hypertrophy markers. Blood 
pressure levels were 7-10 mmHg below normal, likely 
reflecting the endocrine actions of the systemically elevated 
ANP levels. On the other hand, in the mice, cardiac 
hypertrophic responses to aortic constriction were enhanced 
and accompanied by marked deterioration of cardiac 
function, indicating the significant role of cardiomyocyte 
GC-A in physiological as well as in pathophysiological 
conditions.  
  Taken together, these results suggest that the natriuretic 
peptide system exerts a cardioprotective effect that is 
independent of its hemodynamic actions and implicate that 
activation of GC-A signaling has a direct inhibitory effect on 
cellular hypertrophic signaling within the heart [26]. 
The Role of the Local Natriuretic Peptide System in Ang 
II-Induced Cardiac Remodeling 
  However, the precise mechanism by which activation of 
GC-A in cardiomyocytes protects the heart from excessive 
remodeling remained unclear. We previously demonstrated 
that cardiac hypertrophy and fibrosis in GC-A KO mice can 
be significantly diminished by targeted deletion of AT1a 
(double KO for GC-A and AT1a) or by pharmacological 
blockade of the receptor using a selective antagonist [27]. 
Conversely, stimulation of AT1a by exogenous application 
of Ang II, at a dose that does not affect blood pressure 
(subpressor dose), significantly exacerbated cardiac 
hypertrophy and dramatically augmented interstitial fibrosis 
in GC-A-KO mice, but not in wild-type animals. These 
results suggest that cardiac hypertrophy and fibrosis in GC-
A-deficient mice are related, at least in part, to the enhanced 
cardiac AT1a signaling, and that endogenous GC-A inhibits 
the excessive activation of AT1a signaling. 
The Molecular Mechanism by which Cardiac GC-A 
Signaling Exerts its Cardioprotective Effect 
  To identify the differences between the hearts of GC-A 
KO and wild-type mice on a molecular level, we examined 
genes whose expression was upregulated in the hearts of 
GC-A KO mice and found that expression of the product of 
the Down syndrome critical region gene on chromosome 21, 
also called modulatory calcineurin-interacting protein 1 
(MCIP1, more recently RCAN1), was increased. Because 
MCIP1 gene is upregulated by calcineurin signaling, we next 
investigated the role played by calcineurin in the cardiac 
hypertrophy of GC-A KO mice [28] and found that FK506-
mediated blockade of calcineurin activation significantly 
 
Fig. (4). Schematic diagram depicting the pathway via which GC-A signaling inhibits cardiac hypertrophy. Cardiac hypertrophic agonists 
such as Ang II, norepinephrine and endothelin-1 stimulate G-protein-coupled receptors (GPCR) and activate phospholipase C (PLC). 
Subsequent production of inositol triphosphate (IP3) leads to release of Ca
2+ from intracellular stores in the sarcoplasmic reticulum (SR), 
which raises cytosolic Ca
2+ to a level sufficient to activate the calmodulin-regulated phosphatase calcineurin. Once activated, calcineurin 
dephosphorylates the transcription factor nuclear factor of activated T cells (NFAT), which facilitates its nuclear translocation. NFAT and 
GATA then act cooperatively to activate transcription of the hypertrophic gene program, including the ANP and BNP genes. We propose 
that endogenous ANP and BNP exert their antihypertrophic effects by stimulating GC-A/PKG-mediated regulator of G protein signaling 
subtype 4 (RGS4) phosphorylation/activation, which leads RGS4 to associate with Gq, thereby increasing the GTPase activity of Gq. This 
in turn inhibits calcineurin-NFAT signaling and suppresses hypertrophy-related gene transcription. Adopted from reference [29]. Natriuretic Peptide Signaling via Guanylyl Cyclase (GC)-A  Current Cardiology Reviews, 2009, Vol. 5, No. 1    49 
reduced the heart weight to body weight ratio, cardio-
myocyte size, and collagen volume fraction in GC-A KO 
mice, though FK506 had no effect on these parameters in 
wild-type mice. In cultured neonatal cardiomyocytes, 
pharmacological GC-A inhibition increased both basal and 
phenylephrine-stimulated calcineurin activities, while stimu-
lation of GC-A by ANP inhibited these activities. We, 
therefore, suggest that it is by inhibiting calcineurin that 
cardiac GC-A signaling activated by locally secreted 
natriuretic peptides protects the heart from excessive cardiac 
remodeling [28]. To further explore the mechanism of the 
GC-A-mediated inhibition of calcineurin-induced hyper-
trophy, we assessed the G protein signaling that is known to 
occur upstream of calcium-calcineurin signaling and down-
stream of Ang II signaling [29]. It was recently reported that 
cGMP-dependent protein kinase binds directly to and 
phosphorylates/activates regulator of G protein signaling 
subtype 2 (RGS2), which significantly increases the GTPase 
activity of G(q) and terminates G protein-coupled receptor 
signaling in vascular smooth muscle [30]. Given that cGMP 
is an intracellular second messenger for natriuretic peptides, 
we hypothesized that RGS might mediate the cardio-
protective effect of GC-A signaling. To test that idea, we 
focused on RGS4, which is the dominant RGS in 
cardiomyocytes [29, 31]. In cultured cardiomyocytes, ANP 
stimulated the binding of cGMP-dependent protein kinase I 
to RGS4, as well as the phosphorylation of RGS4 and its 
subsequent association with Gq [29]. In addition, 
cardiomyocyte-specific overexpression of RGS4 in GC-A-
KO mice significantly reduced the heart weight to body 
weight ratios, cardiomyocyte size and ventricular calcineurin 
activity. Conversely, overexpression of a dominant-negative 
form of RGS4 blocked the inhibitory effects of ANP on 
endothelin-1-stimulated inositol 1,4,5-triphosphate produc-
tion, [
3H]-leucine incorporation and ANP gene expression. 
These findings suggest that GC-A activates cardiac RGS4, 
which then inhibits the activity of Gq and its downstream 
hypertrophic effectors, thereby playing a key role in the GC-
A-mediated inhibition of cardiac hypertrophy. Fig. (4) shows 
a schematic diagram that depicts the endogenous cardio-
protective mechanism meditated by ANP/BNP, GC-A and 
RGS4.  
CLINICAL IMPLICATIONS 
  The experimental evidence obtained from the various 
animal models summarized above supports the notion that 
GC-A signaling plays a key role in the modulation of cardiac 
remodeling and blood pressure. Several groups have also 
investigated this relationship in human patients. For 
example, Nakayama et al. identified an 8 nucleotides 
insertion/deletion mutation at position -60 (60bp upstream of 
the ATG codon) in the 5'-flanking region (i.e., the promoter 
region) of the human NPR-A (GC-A) gene [32]. After 
genotyping 200 subjects with essential hypertension and 200 
normotensive control subjects, they found nine individuals 
with a deletion that reduced the transcriptional activity of the 
GC-A promoter to less than 30% of the wild-type allele. All 
nine individuals were heterozygous for the allele and 
exhibited hypertension, left ventricular hypertrophy or both, 
suggesting that, in these individuals, this deletion reduces 
receptor expression and confers increased susceptibility to 
essential hypertension or left ventricular hypertrophy. In 
addition, Rubattu et al. investigated the relationships 
between ANP, BNP and GC-A polymorphisms and left 
ventricular structure in approximately 200 subjects with 
essential hypertension [33]. Those investigators identified 
ANP and NPR-A (GC-A) gene variants that were signify-
 
Fig. (5). Transcriptional activities of the indicated (CT)n and 8-bp deletion reporter constructs in human aortic smooth muscle cells. Shown 
are the mean firefly (Luc)/renilla luciferase activity ratios. Note that the GC-A promoter containing (CT)n=6 or the 8bp deletion drove 
significantly less transcriptional activity than the promoter containing (CT)n=10. Modified from reference [34]. 50    Current Cardiology Reviews, 2009, Vol. 5, No. 1  Kishimoto et al. 
cantly associated with left ventricular mass index and left 
ventricular septal thickness. By contrast, BNP polymor-
phisms had no particular effect on cardiac phenotype. They 
concluded that the ANP/NPRA (GC-A) system contributed 
significantly to ventricular remodeling in human essential 
hypertension. 
  We also examined the association between polymor-
phisms within the GC-A promoter and essential hypertension 
in a group of Japanese subjects (177 hypertensive and 170 
normotensive) and identified five allele types in which 6, 9, 
10, 11 or12 CT dinucleotide repeats around position -293, 
upstream of the ATG codon [34]. The frequency of the 
(CT)n=6 allele was significantly higher among hypertensive 
subjects than among normotensive ones, while the 
frequencies of the other four allele types did not differ 
between the two groups. Promoter-reporter analyses carried 
out in cultured human aortic smooth muscle cells using a 
luciferase gene fused to the 5'-flanking region of the GC-A 
gene revealed that, like the promoter containing an 8bp 
deletion at position -60, the promoter containing (CT)n=6 at 
position -293 drove less transcriptional activity than the 
promoter containing (CT)n=10 (control) (Fig. (5)). Our 
results thus define the (CT)n polymorphism in the GC-A 
promoter as a potent and novel hypertension susceptibility 
marker. Although it did not reach statistical significance, 
preliminary data indicate that the incidence of left ventricular 
hypertrophy tends to be higher among patients carrying the 
(CT)n=6 allele than among those carrying other alleles. 
  Collectively, the findings summarized in this section 
suggest that people carrying the certain variants of human 
GC-A gene are more susceptible to cardiovascular diseases 
such as hypertension and cardiac hypertrophy than those 
who do not, possibly because they are resistant to the 
counter-regulation of Gq signaling by ANP/BNP (Fig. (6)). 
CONCLUSION 
  Endogenous GC-A signaling protects the heart from 
excessive remodeling and failure. In addition to the 
improvement of cardiac pre- and after-load, it is suggested 
that GC-A-mediated local activation of RGS protein and 
subsequent suppression of Gq hypertrophic signaling is 
involved in the action. Consequently, individuals who 
express only low levels of GC-A could be genetically prone 
to cardiac remodeling and hypertension. 
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